JOURNAL OF COMPLEMENTARY MEDICINE RESEARCH, 2020
VOL 11, NO. 5

REVIEW ARTICLE

Open Access

Anorectic drugs: an experimental and clinical perspective –A Review

Sindhu Priya K ,Lakshmi.Thangavelu [*],Geetha RV ,Rajeshkumar.S, Raghunandhakumar.S ,Anitha Roy
Undergraduate Student, Department of Pharmacology, Saveetha Dental College, SIMATS, Saveetha University, Chennai, India, Email: lakshmi@saveetha.com
Associate Professor, Department of Pharmacology, Saveetha Dental College, SIMATS, Saveetha University, Chennai, India
Associate Professor, Department of Microbiology, Saveetha Dental College, SIMATS, Saveetha University, Chennai, India

ABSTRACT

Obesity is a highly prevalent disease that continuously rises and is a major problem to solve. It is associated with mortality, morbidity, diet, and treatment costs. The need for new drugs that are effective and long lasting is the primary concern for all health care professionals.

There have been lots of researches recently targeting diabetes, one showed the blockage of sodium-glucose co transporter 2 (SGLT2). It had a high glycemic index and weight-lowering potential. Dual drug therapy was suggested to be highly significant in treating diabetes -2. Fixed dose combination therapy shows an attractive option, since it reduces pill burden and improves adherence. Drugs used was metformin and empagliflozin.

Another research was done in order to acquire a balanced homeostatic energy. Disregulating one of its components can lead to obesity. Altering homeostatic signals can alter the vulnerability for drug abuse. It focuses on single protein target, lorcaslin and orlistat are the main anti-obesity drugs.

Metabolic syndrome is cluster of associated metabolic traits that increases development of CVD and dsiabetes. Seratonergic drugs and inhibitors of pancreatic lipases are used as long-term of obesity. New classes of drugs like glucagon-like peptide 1receptor agonists act on the hunger and satiety centres and favourably impact the associated traits.

ARTICLE HISTORY

Received October 05, 2020
Accepted November 15, 2020
Published December 20, 2020

KEYWORDS

diabetes mellitus, empagliflozin, metformin, metabolic syndrome, drugs

[*] **Contact**: Lakshmi.Thangavelu *Undergraduate Student, Department of Pharmacology, Saveetha Dental College, SIMATS, Saveetha University, Chennai, India,* lakshmi@saveetha.com

INTRODUCTION

Diabetes is a group of metabolic disease referred to as diabetes mellitus, which have a high blood glucose levels. It has been estimated that 22 million Americans have diabetes. In the study done in university of Nebraska, suggested the use of metformin (MET) as it reduced the hemoglobin A1c[1]. But patients with type 2 diabetes, they were not able toad euglycemia with MET alone and required other medical treatments. The second agent for the medication of type 2 diabetes, have not been fully analysed. There are ongoing trials for the determination of an ideal agent.

The inhibitor for sodium-glucose transporter is the newest method of treating diabetes, as they increase the excretion of excess glucose present in blood into urine[2]. This mechanism in patients having type 2 diabetes, is the better dealt with as they have a high threshold for renal excretion and an up regulation of SGLT 2.

The efficacy of the treatment depends on the adherence of patients to their medication, and previous studies have estimated to be 50%. If it is a oral medication the estimation increases to 65-85%. Decreased adherence to patients of less than 80%, increases their risk of hospitalisation. In a study of using combination therapy, it has showed that there is 26% increase in the adherence rate. The main reason for alteration in the patients medication adherence is if the patients have hypoglycaemia[3].

In Another observational study, conducted by Jean vague in 1947, had found an association between obesity, diabetes and hypertension. And this linked traits were expanded with the addition of hypertriglyceridemia and hyperinsulinemia by Albrinks[4].This is an example of metabolic syndrome and it links it to type 2 diabetes.

National cholesterol educational programme concluded a criteria, to meet the criteria 3 of 5 factors were established; abdominal obesity, elevated triglycerides, reduced high density lipoproteins, increased blood pressure[5], and impaired fasting glucose. An extra addition was added to this criteria to help the diagnosis, polycystic ovary syndrome, hyperuricemia, and family history of CVD and diabetes 2.

In another study conducted in MEDLINE, LILACS TRIALS, fenproporex is structurally similar to amphytamine and when fenproporex is metabolised in the body it is converted to amphytamine and excreted in urine[6]. This has stimulatory affects and that is reason it is used for treating obese people with CVD. It was added to diet pills as it had weight loss actions and therefore used to treat overweight and obesity. It's side affects are drug abuse, mood changes and psychiatric disorders.

Desoxyephedrine was approved instead of fenproporex because fenproporex has high side effects[7].

SGLT-2 inhibition drugs

Hepatic impairment

Changes in dose are not required for EMPA in patients with hepatic impairment. EMPA is for the mostly killed in defecation (41.2%) or urine (54.4%), while 90% of the ingested MET is discharged unaltered in urine in the rest 24 hours. However, there is a discovery cautioning for MET that it can bring about lactic acidosis from MET accumulation[8]. An expanded danger of lactic acidosis is found in states of: renal and hepatic disability, intense congestive heart disappointment, sepsis, dehydration, and abundance liquor consumption. In the event that acidosis is suspected, then prompt end of the medication is suggested alongside hospitalisation of the patient. The mix of MET and SGLT-2 inhibitors ought to be kept away from patients with hepatic debilitation[9].

Geriatric

There is no suggestion to change the measurements of EMPA and MET blend in matter of increase in age. Increased age does not have an effect of pharmacokinetics of EMPA. Adverse impacts of EMPA, for example, the danger of urinary tract contaminations are more incessant in patients with 75 years of age. Also, the freedom of MET is diminished in elderly subjects thus of age-related decrease in eGFR and warrants renal capacity monitoring[10].

Pregnancy

The utilisation of blend of MET and EMPA in pregnancy has a pregnancy classification C chance, which demonstrates that there are no human reviews in pregnant ladies with EMPA and animal studies have demonstrated an unfriendly impact. EMPA may influence fatal kidney advancement and maturation. Manufacturer's information suggest illuminating female patients of childbearing age that the medication has not been contemplated in pregnancy and ought to just be utilised as a part of pregnancy if the potential advantage exceeds the hazard to the foetus[11]. The utilisation of MET has a pregnancy class B chance. There has not been proof to propose mischief to the foetus; in any case, MET crosses into the placenta. The utilisation of MET is a possibility for glycemic control in both T2DM and gestational DM.

Lactation

There are no present clinical reviews that have been done as far as anyone is concerned to examine if EMPA is discharged into breast milk. MET is discharged in breast milk at low levels and

does not seem to affect the newborn child growth[12].

Drug interaction

EMPA does not interface with cytochrome P450 isoforms. In this way, EMPA does not influence correspondingly controlled medications that are substrates of the major CYP450 isoforms. In sound volunteers, EMPA did not communicate with other anti-diabetic pharmaceuticals (MET, sitagliptin, linagliptin), simvastatin, antihypertensive medicines (hydrochlorothiazide, toresmide) digoxin, and oral prophylactic pills. MET can possibly collaborate with cationic-like amiloride, morphine, ranitidine, and vancomycin that are discharged by tubular secretion[13]. Cautious utilisation of carbonic anhydrase inhibitors, for example, zonisamide, and topiramate is suggested on the grounds that they can prompt metabolic acidosis.

Treatment of metabolic syndrome

Clinical management

The objective for subjects with the metabolic disorder and diabetes is to decrease their hazard for atherosclerotic illness and diabetes. In spite of huge examination being developed of medications for diabetes and metabolic disorder, to date, achievement has been chiefly restricted to surgical mediations when contrasted with eating regimen or pharmacotherapy. Eat less carbs in immersed and trans fats, with aggregate fat substance of 25% to 35% of calories are regularly suggested yet have unobtrusive accomplishment in restricting infection because of poor adherence. Perseverance practice invigorates oxidative phosphorylation and mitochondrial size and number, and, together with pharmacotherapy, may help in lessening the danger of metabolic disorder. While the way of life, for example, physical action, weight lessening, and eating routine can have sensational impacts at individual level, they are deficient at populace levels[14].

Established Medical Therapy for Risk Factor Management in Metabolic Syndrome

There are a few genuinely entrenched pharmacotherapies in treatment of metabolic hazard elements and counteractive action of cardiovascular complications. The objective for antihypertensive treatment in patients of 60 years of age is accomplishing a circulatory strain of <140/90 mm Hg. Most information support the utilisation of angiotensin-converting enzyme (ACE) inhibitors as first-line treatment for hypertension in subjects with metabolic disorder and type 2 diabetes mellitus, CAD or perpetual kidney infection[15]. One explanation behind this inclination is the unfriendly impacts of most other antihypertensive pharmaceuticals. While diuretics are the most ordinarily utilised against hypertensive medications, these may build the possibility of move out diabetes mellitus in patients with metabolic disorder.

Various medications utilised as part of treatment of metabolic hazard elements have been appeared to adequately lessen irritation measured by plasma CRP levels, including statins, fibrates and thiazolidinediones (TZD)[16]. The last two target atomic receptors Peroxisome Proliferator-Activated Receptors (PPAR) alpha and gamma, separately. TZDs enhance insulin affect-ability by decreasing ectopic fat deposition in the skeletal muscle and redistribution of fat into fat tissue.

Anti-obesity drugs

There are a few alternatives for pharmacotherapy for diabetes. Utilisation of diabetes medications is endorsed for patients with a BMI more prominent than 30, or BMI > 27 when at least one comorbidities, for example, hypertension or diabetes are available. At the point when consolidated with way of life adjustments, tranquillise treatment can for the most part enhance weight reduction by 3–5 kg over fake treatment[17]. While this misfortune is humble, it might be helpful to include pharmacotherapy when patients experience a level in getting in shape with way of life changes alone. It is essential to note, in any case, that long haul treatment is required, as weight reduction ascribed to the medication treatment is recovered when the medication is ended. The new worldview is that medication treatment is required long lasting life. Resistance can create and pick up happens even with the regular medication regimen. Irregular dosing is being investigated as a potential technique to avert resilience amid long haul treatment.

The most punctual medications that are still being used for obesity have a place with amphetamine subsidiaries like phentermine, desoxyephedrine, and diethylpropion. These medications are midway acting sympathomimetics with undesired impacts on focal sensory system, for example, disturbance, mind flights, uncontrolled muscle developments, tipsiness, trouble dozing, touchiness, queasiness heaving[18]. Resistance grows quickly to these specialists. In that capacity, these are affirmed for 12-week treatment. As expanded heart rate can be an unfriendly impact, treatment with this medication class alone is not ideal for obese patients.

Lorcaserin (Belviq) is a craving suppressant and weight reduction tranquillise with serotoninergic properties that was initially dismissed by the FDA in light of worries about tumour development in preclinical reviews however was at long last

affirmed. Sedate Enforcement Administration has characterised it since 2013 as a Schedule IV tranquillise under the Controlled Substances Act[19]. On account of worries about tumour development, danger of psychiatric issue and valvular infection, Arena Pharmaceutical pulled back its promoting approval application for Lorcaserin in Europe.

Tesofensine (NS2330) is a serotonin–noradrenaline–dopamine re-uptake inhibitor from the phenyltropane group of medications, which is as of now being worked on for treatment of obesity. Tesofensine has finished Phase 1 and 2 trials. It principally goes about as a hunger suppressant, however potentially acts by expanding resting energy consumption. The distributed stage 2 trial indicated promising levels of weight reduction, more prominent than those accomplished by some other accessible medications[20]. It is presently in advanced Phase 3 testing, however has as of late been under investigation for genuine symptoms. The most well-known reactions incorporate dry mouth, cerebral pain, sleep deprivation, and gastrointestinal manifestations, circulatory strain and heart rate rise.

Glucagon-like peptide 1 receptor (GLP-1R) agonists are medications that are authorised for the treatment of type 2 diabetes. Glucagon-like pepetide-1 (GLP-1) is a gut hormone that is discharged by the endocrine L-cells after nourishment admission. It depresses glucagon generation, animates pancreatic insulin discharge, delays gastric purging and has been appeared to advance satiety (Turton et al., 1996). Since GLP-1 has a short half-life and is corrupted by the universal catalyst dipeptidyl-peptidase IV (DPP-IV), different targets, for example, DPP-IV inhibitors, DPP-IV-safe exendin-4 and GLP-1R might be more reasonable for clinical advancement. Huge measurements of GLP-1R agonist liraglutide can instigate satiety in the focal sensory system and accomplish huge weight reduction and enhance insulin affect-ability[21][22].

Receptor-communicating protein-140 (RIP140, otherwise known as NCOR2) is an atomic hormone co-repressor, which controls fat depletion. It collaborates with atomic receptors such oestrogen, thyroid hormone and retinoic corrosive receptors through 2 C-terminal receptor-cooperating areas (RIDs).

Safety and efficacy of Fenproporex

This systematic review demonstrated that there is a scarcity of randomised, placebo treatment controlled trials on the efficacy and safety of FEN for treating overweight (BMI > 25 kg/m2) and obesity (BMI > 30 kg/m2). A search in the MEDLINE, LILACS, and Cochrane Controlled Trial Register databases found a randomised, controlled clinical trial distributed in 2014, while three placebo treatment controlled reviews, one of which non-randomised, were identified by scanning for investigations in non-indexed medicinal journals. Four controlled trials reliably demonstrated that FEN prompted body weight misfortunes more prominent than that connected with placebo treatment utilisation. An arrangement of methodological laws, in any case, vitiates conclusions in light of their endings. Randomisation, blinding, and treatment of missing information because of attrition are awed in these clinical trials. In addition, all reviews are underpowered to distinguish differences amongst control and FEN-treated gatherings with respect to the event of unfavourable effects.

Random task and disguised designation of patients are viewed as the best insurance against systematic differences between patterned qualities of groups being compared. Non-random group assignments made by clinical examiners can be identified with prognosis and responsiveness to treatment[23]. Since these reports of placebo treatment controlled trials gave insufficient data on the randomisation and allotment concealing forms, it can't be determined whether objectives of randomisation were effectively proficient.

Weakening rates are for the most part high in long-term randomised, controlled clinical trials on suppressants and limit the understanding of information on their efficacy and wellbeing. Besides, on the off chance that one arm of the trial has a wearing down rate higher than the other, the randomisation is disabled. Bias in attrition may happen if patients who finished the trial are deliberately different from the individuals who neglected to do it. Systematic mistakes brought on by attrition, be that as it may, can be lessened or kept away from if examination of result information depends on initial randomised task (i.e., goal to-treat investigation) and not on the treatment received in the end, and specialists utilise ascription techniques (e.g., last observation carried out forward) to handle missing information. Just two studies utilised goal to-treat investigation to assess whether FEN was more effective than placebo treatment in advancing weight reduction[24-41].

Just four controlled reviews met the inclusion criteria. One randomised, placebo treatment controlled trial on Fenproporex was found on electronic databases. Three placebo treatment controlled reviews (in non-indexed journals) were discovered by hand-searching. Patients with cardiovascular and different comorbidities were barred in all reviews. Trials endured from 40 to 364 days and measurements went from 20 to 33.6 mg/d. All controlled reviews found that weight

reduction among Fenproporex treated patients was more prominent than that created by the placebo treatment, yet drug effect modest. Fenproporex delivered extra weight decreases of 4.7 kg (one year), 3.8 kg (six months) and 1.55 kg (two months) in normal, in connection to eating regimen and exercise only (three trials). A sleeping disorder, irritability, and nervousness were the most announced side effects in the four reviews[25].

CONCLUSION

There is a lack of randomised, placebo treatment controlled trials on Fenproporex and those discovered here present major methodological errors. These examines recommend that Fenproporex is unobtrusively effective in advancing weight reduction. In any case, they neglected to give evidence that it diminishes obesity related mortality. Information from these reviews are insufficient to decide the hazard and benefit of Fenproporex. Abuse potential and amphetamine-like side effects are foundations for concern.

The utilisation of combination treatment will probably diminish pill load, rearrange the diabetes regimen, and enhance adherence rate contrasted with single-segment prescriptions. This may prompt to enhanced clinical results and cost savings. Notwithstanding glycemic control, EMPA and MET may prompt to weight reduction and enhanced blood pressure control, which will enhance the patients' general clinical condition.

REFERENCE

1. Attié Jr M, Medeiros-Neto GA. Administração de fenproporex sob a forma duplamente cega a pacientes com obesidade exógena: análise de resultados terapêuticos e efeitos no metabolismo lipídico. Folha Med. 1972;64(4):705-14.
2. Beckett AH, Shenoy EV, Salmon JA. The in uence of replacement of the N-ethyl group by the cyanoethyl group on the absorption, distribution and metabolism of (plus or minus)-ethylamphetamine in man. J Pharm Pharmacol. 1972;24(3):194-202. DOI:10.1111/j.2042-7158.1972.tb08964.x
3. Chiorboli E, Scazufca AV. Emprego clínico de nova forma farmacêutica no tratamento da hiperorexia em obesidade exógena. Folha Med. 1975;71(4):425-30.
4. Cody JT, Valtier S. Detection of amphetamine following administration of fenproporex. J Anal Toxicol. 1996;20(6):425-31. DOI:10.1093/jat/20.6.425
5. Cody JT, Valtier S, Stillman S. Amphetamine and fenproporex levels following multidose administration of fenproporex. J Anal Toxicol. 1999;23(3):187-94. DOI:10.1093/jat/23.3.187
6. Cohen PA. Imported fenproporex-based diet pills from Brazil: a report of two cases. J Gen Intern Med. 2009;24(3):430-3. DOI:10.1007/s11606-008-0878-4
7. Cohen PA, Goday A, Swann JP. The return of rainbow diet pills. Am J Public Health. 2012;102(9):1676-86. DOI:10.2105/AJPH.2012.300655
8. Colman E. Anorectics ontrial: a half century of federal regulation of prescription appetitesuppressants. Ann Intern Med. 2005;143(5):380-5. DOI:10.7326/0003-4819-143-5-200509060-00013
9. Comiran E, Souza DZ, Boehl PO, Cássia Mariotti K, Pechansky F, Duarte PCAV et al. Fenproporex and amphetamine pharmacokinetics in oral uid after controlled oral administration of fenproporex. Ther Drug Monit. 2012;34(5):545-53. DOI:10.1097/FTD.0b013e318263c6c5
10. Coronho V, Pena RM. Avaliação clínica do fenproporex no tratamento da obesidade. Folha Med. 1973;66(1):99-112.
11. Coutts RT, Nazarali AJ, Baker GB, Pasutto FM. Metabolism and disposition of N-(2-cyanoethyl) amphetamine (fenproporex) and amphetamine: study in the rat brain. Can J Physiol Pharmacol. 1986;64(6):724-8. DOI:10.1139/y86-122
12. Dinato MC, Fraige Filho F, Medeiros- Neto GA. Aspectos metabólicos do tratamento da obesidade com anorexígeno de ação prolongada. Folha Med. 1975;71(6):641-6.
13. Faivre G, Dodinot B, Hua G. Traitement de l'obesité chez les cardiaques experimentation d'un nouvel anorexigene. Vie Med.1969;2:730-4.
14. Hertel G, Fallot-Burghardt W. Behandlung adipöser Patientinnen mit Fenproporex im Rahmen einer gynäkologischen Fachpraxis. Fortschr Med. 1978;96(47-48):2380-2.
15. Horie NC, Cercato C, Mancini MC, Halpern A. Long-term pharmacotherapy for obesity in elderly patients: a retrospective evaluation of medical records from a specialized obesity outpatient clinic. Drugs Aging. 2010;27(6):497-506. DOI:10.2165/11536660-000000000-00000
16. James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905-17. DOI:10.1056/NEJMoa1003114
17. Kraemer T, Theis GA, Weber AA, Maurer HH. Studies on the metabolism and toxicological detection of the amphetamine-like anorectic fenproporex in human urine by gas chromatography-mass spectrometry and

uorescence polarization immunoassay. J Chromatogr B Biomed Sci Appl. 2000;738(1):107-18. DOI:10.1016/S0378-4347(99)00497-1
18. Luz P. Resultados terapêuticos do fenproporex no obeso ambulatorial. Folha Med. 1974;68(4):351-4.
19. Machado ACC, Vieira MA, Távora A, Machado RJC, Medeiros AK, Leite V et al. Avaliação da associação da terapêutica medicamentosa e a terapia cognitivo-comportamental no tratamento da obesidade. RBM Rev Bras Med. 2002;59(1-2):47-53.
20. Oury P, Duché G. Étude de l'action lipolytique du fenproporex dans l'obésité par la mesure du pli cutané. Therapeutique. 1970;46(5):551-5.
21. Pélissier-Alicot AL, Piercecchi-Marti MD, Bartoli C, Kuhlmann E, Coiffait PE, Sanvoisin A et al. Abusive prescription of psychostimulants: a study of two cases. J Forensic Sci. 2006;51(2):407-10. DOI:10.1111/j.1556-4029.2006.00078.x
22. American Diabetes Association. 7 approaches to glycemic treatment. Diabetes Care. 2016;39(suppl 1):S52–S59.
23. Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012;35(2):446–454.
24. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443.
25. NathanDM,BuseJB,KahnSE,etal;GRADEStudyReSearchGroup. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013; 36(8):2254–2261.
26. Gopalakannan, S., Senthilvelan, T. and Ranganathan, S., 2012. Modeling and optimization of EDM process parameters on machining of Al 7075-B4C MMC using RSM. Procedia Engineering, 38, pp.685-690.
27. Venu, H., Raju, V.D. and Subramani, L., 2019. Combined effect of influence of nano additives, combustion chamber geometry and injection timing in a DI diesel engine fuelled with ternary (diesel-biodiesel-ethanol) blends. Energy, 174, pp.386-406.
28. Lekha, L., Raja, K.K., Rajagopal, G. and Easwaramoorthy, D., 2014. Schiff base complexes of rare earth metal ions: Synthesis, characterization and catalytic activity for the oxidation of aniline and substituted anilines. Journal of Organometallic Chemistry, 753, pp.72-80.
29. Krishnamurthy, A., Sherlin, H.J., Ramalingam, K., Natesan, A., Premkumar, P., Ramani, P. and Chandrasekar, T., 2009. Glandular odontogenic cyst: report of two cases and review of literature. Head and neck pathology, 3(2), pp.153-158.
30. Parthasarathy, M., Lalvani, J.I.J., Dhinesh, B. and Annamalai, K., 2016. Effect of hydrogen on ethanol–biodiesel blend on performance and emission characteristics of a direct injection diesel engine. Ecotoxicology and environmental safety, 134, pp.433-439.
31. Shuang Wu, Shanmugam Rajeshkumar, Malini Madasamy & Vanaja Mahendran (2020) Green synthesis of copper nanoparticles using Cissus vitiginea and its antioxidant and antibacterial activity against urinary tract infection pathogens, Artificial Cells, Nanomedicine, and Biotechnology, 48:1, 1153-1158,
32. Thangavelu, L., Balusamy, S.R., Shanmugam, R., Sivanesan, S., Devaraj, E., Rajagopalan, V., Nallaswamy, D., Chellapan, D.K., Dua, K., Kim, Y.J. and Perumalsamy, H., 2020. Evaluation of the sub-acute toxicity of Acacia catechu Willd seed extract in a Wistar albino rat model. Regulatory Toxicology and Pharmacology, p.104640.
33. PradeepKumar, A.R., Shemesh, H., Jothilatha, S., Vijayabharathi, R., Jayalakshmi, S. and Kishen, A., 2016. Diagnosis of vertical root fractures in restored endodontically treated teeth: a time-dependent retrospective cohort study. Journal of Endodontics, 42(8), pp.1175-1180.
34. Neelakantan, P., Grotra, D. and Sharma, S., 2013. Retreatability of 2 Mineral Trioxide Aggregate–based Root Canal Sealers: A Cone-beam Computed Tomography Analysis. Journal of endodontics, 39(7), pp.893-896.
35. Sajan, D., Lakshmi, K.U., Erdogdu, Y. and Joe, I.H., 2011. Molecular structure and vibrational spectra of 2, 6-bis (benzylidene) cyclohexanone: A density functional theoretical study. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 78(1), pp.113-121.
36. Uthrakumar, R., Vesta, C., Raj, C.J., Krishnan, S. and Das, S.J., 2010. Bulk crystal growth and characterization of non-linear optical bisthiourea zinc chloride single crystal by unidirectional growth method. Current Applied Physics, 10(2), pp.548-552.
37. Neelakantan, P., Cheng, C.Q., Mohanraj, R., Sriraman, P., Subbarao, C. and Sharma, S., 2015. Antibiofilm activity of three irrigation protocols activated by ultrasonic, diode laser or Er: YAG laser in vitro. International endodontic journal, 48(6), pp.602-610.
38. Neelakantan, P., Sharma, S., Shemesh, H. and Wesselink, P.R., 2015. Influence of irrigation sequence on the adhesion of root canal sealers

to dentin: a Fourier transform infrared spectroscopy and push-out bond strength analysis. Journal of endodontics, 41(7), pp.1108-1111.
39. Prathibha, K.M., Johnson, P., Ganesh, M. and Subhashini, A.S., 2013. Evaluation of salivary profile among adult type 2 diabetes mellitus patients in South India. Journal of clinical and diagnostic research: JCDR, 7(8), p.1592.
40. Rajeshkumar, S., Kumar, S.V., Ramaiah, A., Agarwal, H., Lakshmi, T. and Roopan, S.M., 2018. Biosynthesis of zinc oxide nanoparticles usingMangifera indica leaves and evaluation of their antioxidant and cytotoxic properties in lung cancer (A549) cells. Enzyme and microbial technology, 117, pp.91-95.
41. Francis T, Rajeshkumar S, Roy A, Lakshmi T. Anti-inflammatory and Cytotoxic Effect of Arrow Root Mediated Selenium Nanoparticles. Pharmacogn J. 2020;12(6):1363-7.
42. Patil, S. B., Durairaj, D., Kumar, G. S., Karthikeyan, D. and Pradeep, D., Comparison of Extended Nasolabial Flap Versus Buccal Fat Pad Graft in the Surgical Management of Oral Submucous Fibrosis: A Prospective Pilot Study, Journal of Maxillofacial & Oral Surgery, 2017, 16(3):312-321
43. Sahu, D., Kannan, G. M. and Vijayaraghavan, R., Carbon Black Particle Exhibits Size Dependent Toxicity in Human Monocytes, International Journal of Inflammation, 2014, 2014:10
44. Jeevanandan, G. and Govindaraju, L., Clinical comparison of Kedo-S paediatric rotary files vs manual instrumentation for root canal preparation in primary molars: a double blinded randomised clinical trial, European Archives of Paediatric Dentistry, 2018, 19(4):273-278
45. Wahab, P. U. A., Nathan, P. S., Madhulaxmi, M., Muthusekhar, M. R., Loong, S. C. and Abhinav, R. P., Risk Factors for Post-operative Infection Following Single Piece Osteotomy, Journal of Maxillofacial & Oral Surgery, 2017, 16(3):328-332
46. Eapen, B. V., Baig, M. F. and Avinash, S., An Assessment of the Incidence of Prolonged Postoperative Bleeding After Dental Extraction Among Patients on Uninterrupted Low Dose Aspirin Therapy and to Evaluate the Need to Stop Such Medication Prior to Dental Extractions, Journal of Maxillofacial & Oral Surgery, 2017, 16(1):48-52
47. Menon, S., Devi, K. S. S., Santhiya, R., Rajeshkumar, S. and Kumar, S. V., Selenium nanoparticles: A potent chemotherapeutic agent and an elucidation of its mechanism, Colloids and Surfaces B-Biointerfaces, 2018, 170:280-292.
48. Wahab, P. U. A., Madhulaxmi, M., Senthilnathan, P., Muthusekhar, M. R., Vohra, Y. and Abhinav, R. P., Scalpel Versus Diathermy in Wound Healing After Mucosal Incisions: A Split-Mouth Study, Journal of Oral and Maxillofacial Surgery, 2018, 76(6):1160-1164
49. Krishnamurthy, A., Sherlin, H. J., Ramalingam, K., Natesan, A., Premkumar, P., Ramani, P. and Chandrasekar, T., Glandular Odontogenic Cyst: Report of Two Cases and Review of Literature, Head & Neck Pathology, 2009, 3(2):153-158
50. Prasad, SV; Kumar, M; Ramakrishnan, M; Ravikumar, D Report on oral health status and treatment needs of 5-15 years old children with sensory deficits in Chennai, India,2018,38(1):58-59
51. Uthrakumar, R; Vesta, C; Raj, CJ; Krishnan, S; Das, SJ Bulk crystal growth and characterization of non-linear optical bisthiourea zinc chloride single crystal by unidirectional growth method,2010,10(2):548-552.
52. Ashok, BS; Ajith, TA; Sivanesan, S Hypoxia-inducible factors as neuroprotective agent in Alzheimer's disease2017,44(3):327-334
53. Neelakantan, P; Sharma, S; Shemesh, H; Wesselink, PR Influence of Irrigation Sequence on the Adhesion of Root Canal Sealers to Dentin: A Fourier Transform Infrared Spectroscopy and Push-out Bond Strength Analysis,2015,41(7):1108-1111.
54. Haribabu, K; Muthukrishnan, S; Thanikodi, S; Arockiaraj, GA; Venkatrama, Investigation Of Air Conditioning Temperature Variation By Modifying The Structure Of Passenger Car Using Computational Fluid Dynamics,2020,24(1):495-498